Department of Psychology, University of Bologna, Bologna, Italy.
Department of Psychiatry, University at Buffalo, State University of New York, Buffalo.
JAMA Psychiatry. 2021 Mar 1;78(3):261-269. doi: 10.1001/jamapsychiatry.2020.3650.
The sequential model emerged from the awareness that the persistence of residual symptoms and the frequent occurrence of psychiatric comorbidity were both associated with poor long-term outcome of major depressive disorder (MDD).
To conduct an updated meta-analysis to examine the association of the sequential combination of pharmacotherapy and psychotherapy with reduced risk of relapse and recurrence in MDD.
Keyword searches were conducted in PubMed, PsycInfo, Web of Science, and the Cochrane Library from inception of each database through November 2019. Reference lists from relevant studies were examined using the following keywords: sequential treatment, drugs and psychotherapy, combined treatment, continuation or maintenance, relapse or recurrence and prevention, and depress* or major depress*, selecting adults and randomized controlled trials as additional limits. Authors of selected articles were contacted if needed.
Randomized clinical trials examining the effectiveness of the sequential use of psychotherapy following response to acute-phase pharmacotherapy in the treatment of adult remitted patients with MDD were selected independently by 2 reviewers.
The methods used fulfilled the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Data extraction and methodologic quality assessment were conducted independently by the reviewers. Examination of the pooled results was performed based on the random-effects model. Heterogeneity between study results and likelihood of significant publication bias were assessed. Sensitivity analyses and meta-regressions were also run.
The primary outcome measures were relapse or recurrence rates of MDD, as defined by study investigators, at the longest available follow-up.
Seventeen randomized clinical trials met criteria for inclusion in the meta-analysis, with 1 study yielding 2 comparisons (2283 patients overall, with 1208 patients in a sequential treatment arm and 1075 in a control arm). The pooled risk ratio for relapse/recurrence of MDD was 0.84 (95% CI, 0.74-0.94), suggesting a relative advantage in preventing relapse/recurrence for the sequential combination of treatments compared with control conditions.
The results of this systematic review and meta-analysis indicate that the sequential integration of psychotherapy following response to acute-phase pharmacotherapy, alone or combined with antidepressant medication, was associated with reduced risk of relapse and recurrence in MDD. The preventive value of the sequential strategy relies on abatement of residual symptoms and/or increase in psychological well-being. The steps for implementing the sequential approach in remitted patients with recurrent MDD are provided.
从意识中出现的序列模型表明,残留症状的持续存在和精神共病的频繁发生都与重度抑郁症(MDD)的长期预后不良有关。
进行更新的荟萃分析,以检查药物治疗和心理治疗的序贯联合是否与降低 MDD 的复发和复发风险相关。
从每个数据库的开始到 2019 年 11 月,通过在 PubMed、PsycInfo、Web of Science 和 Cochrane 图书馆中进行关键词搜索。使用以下关键词检查相关研究的参考文献列表:序贯治疗、药物和心理治疗、联合治疗、延续或维持、复发或复发和预防以及抑郁或重度抑郁,选择成年人和随机对照试验作为附加限制。如果需要,与选定文章的作者联系。
由 2 名独立评审员选择独立审查的、在急性相药物治疗后对成人缓解患者进行心理治疗的序贯使用效果进行的随机临床试验。
使用的方法符合系统评价和荟萃分析的首选报告项目(PRISMA)报告准则。数据提取和方法质量评估由评审员独立进行。根据随机效应模型进行汇总结果的检查。评估研究结果之间的异质性和显著发表偏倚的可能性。还进行了敏感性分析和荟萃回归。
主要结果是研究人员定义的 MDD 的复发或复发率,最长的可用随访时间。
17 项随机临床试验符合纳入荟萃分析的标准,其中 1 项研究产生了 2 项比较(共 2283 例患者,1208 例患者在序贯治疗组,1075 例在对照组)。MDD 复发/复发的风险比为 0.84(95%CI,0.74-0.94),这表明与对照条件相比,治疗的序贯组合在预防复发/复发方面具有相对优势。
这项系统评价和荟萃分析的结果表明,单独或与抗抑郁药联合使用急性相药物治疗后的心理治疗的序贯整合与降低 MDD 的复发和复发风险相关。序贯策略的预防价值依赖于残留症状的减轻和/或心理幸福感的提高。为缓解复发的 MDD 缓解患者实施序贯方法的步骤提供。